Helixgate

Helixgate

Uncategorized

What you need to know about hantavirus (don’t panic)

Good morning. Yesterday, the writer Yiyun Li won a Pulitzer Prize for her heartbreaking memoir, “Things in Nature Merely Grow.” Lately, I’ve been reading her short stories. Here’s one for after you’ve read the news, about a health care worker of sorts: “A Sheltered Woman.” 

The latest on the abortion pill

A Monday order from the Supreme Court, signed by Justice Samuel Alito, temporarily restored broad access to mifepristone after a federal appeals court ruling on Friday jeopardized access to the abortion medication at pharmacies or through the mail. The Supreme Court order will remain in effect until the end of the day next Monday, giving both sides time to respond while the court considers the issue. The AP has more details.

Read the rest…

Read More

Published

on

Good morning. Yesterday, the writer Yiyun Li won a Pulitzer Prize for her heartbreaking memoir, “Things in Nature Merely Grow.” Lately, I’ve been reading her short stories. Here’s one for after you’ve read the news, about a health care worker of sorts: “A Sheltered Woman.” 

The latest on the abortion pill

A Monday order from the Supreme Court, signed by Justice Samuel Alito, temporarily restored broad access to mifepristone after a federal appeals court ruling on Friday jeopardized access to the abortion medication at pharmacies or through the mail. The Supreme Court order will remain in effect until the end of the day next Monday, giving both sides time to respond while the court considers the issue. The AP has more details.

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Vertex earnings get muted investor response

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

Read More

Published

on

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

Read More

Continue Reading

Uncategorized

Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution

Published

on

While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.

Continue Reading

Uncategorized

Foundayo’s liver failure blip weighs down Lilly shares. but analysts unconcerned

Published

on

The selloff in Eli Lilly’s shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety profile of Foundayo remains favorable.

Continue Reading
Advertisement

Trending